Topically administered macromolecular heparin proteoglycans inhibit thrombus growth in microvascular anastomoses.
Identifieur interne : 003432 ( Main/Exploration ); précédent : 003431; suivant : 003433Topically administered macromolecular heparin proteoglycans inhibit thrombus growth in microvascular anastomoses.
Auteurs : RBID : pubmed:11858484English descriptors
- KwdEn :
- Administration, Topical, Anastomosis, Surgical, Animals, Blood Coagulation Tests, Femoral Artery (surgery), Femoral Artery (ultrastructure), Fibrinolytic Agents (administration & dosage), Fibrinolytic Agents (therapeutic use), Heparin (administration & dosage), Heparin (analogs & derivatives), Heparin (therapeutic use), Indium Radioisotopes (analysis), Male, Microscopy, Electron, Scanning, Models, Animal, Platelet Adhesiveness (drug effects), Proteoglycans (administration & dosage), Proteoglycans (therapeutic use), Rats, Rats, Inbred BN, Rats, Inbred Strains, Thrombosis (prevention & control), Vascular Patency (drug effects).
- MESH :
- chemical , administration & dosage : Fibrinolytic Agents, Heparin, Proteoglycans.
- chemical , analogs & derivatives : Heparin.
- chemical , analysis : Indium Radioisotopes.
- drug effects : Platelet Adhesiveness, Vascular Patency.
- prevention & control : Thrombosis.
- surgery : Femoral Artery.
- chemical , therapeutic use : Fibrinolytic Agents, Heparin, Proteoglycans.
- ultrastructure : Femoral Artery.
- Administration, Topical, Anastomosis, Surgical, Animals, Blood Coagulation Tests, Male, Microscopy, Electron, Scanning, Models, Animal, Rats, Rats, Inbred BN, Rats, Inbred Strains.
Abstract
Previously, during blood perfusion over collagen-coated surfaces; soluble or immobilized heparin proteoglycans (HEP-PG) have been shown to block thrombus growth. Our aim was to study the antithrombotic effect of locally applied unfractionated heparin (UFH, 1 mg/ml), or rat mast cell-derived HEP-PG (MW 750 kD, 10 microg/ml) compared with saline in early (10 min) and late (3 days) thrombus formation upon anastomosis of rat common femoral arteries. In both semiquantitative scanning electron microscopy (SEM) and quantitative platelet Indium 111-labeling HEP-PG inhibited thrombus growth in comparison with saline. At 10 min, the extent of thrombosis (scale 1-4) in SEM followed the order: saline (3.2+/-0.8) > UFH (2.8+/-1.0) > HEP-PG (1.8+/-0.8), and also Indium 111-positive platelets (10(6)) accumulated on the anastomosed vessel in the same order 14.2 +/-7.2, 10.3 +/-5.0, and 7.7 +/-3.1 (saline vs. HEP-PG, p = 0.03 and 0.05, respectively). At 3 days all HEP-PG-treated vessels remained patent with only small mural thrombi, whereas 2/7 saline- and 1/7 UFH-treated anastomoses occluded and showed more thrombosis overall. We conclude that locally administered HEP-PG inhibit arterial thrombus growth in anastomosed small-sized arteries and could prevent thrombotic complications in (micro)vascular surgery and arteriovenous shunts.
PubMed: 11858484
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Topically administered macromolecular heparin proteoglycans inhibit thrombus growth in microvascular anastomoses.</title><author><name sortKey="Olsson, Eija" uniqKey="Olsson E">Eija Olsson</name><affiliation wicri:level="1"><nlm:affiliation>Department of Plastic Surgery, Helsinki University Central Hospital, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Plastic Surgery, Helsinki University Central Hospital</wicri:regionArea></affiliation></author><author><name sortKey="Asko Seljavaara, Sirpa" uniqKey="Asko Seljavaara S">Sirpa Asko-Seljavaara</name></author><author><name sortKey="Lassila, Riitta" uniqKey="Lassila R">Riitta Lassila</name></author></titleStmt><publicationStmt><date when="2002">2002</date><idno type="RBID">pubmed:11858484</idno><idno type="pmid">11858484</idno><idno type="wicri:Area/Main/Corpus">003812</idno><idno type="wicri:Area/Main/Curation">003812</idno><idno type="wicri:Area/Main/Exploration">003432</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Topical</term><term>Anastomosis, Surgical</term><term>Animals</term><term>Blood Coagulation Tests</term><term>Femoral Artery (surgery)</term><term>Femoral Artery (ultrastructure)</term><term>Fibrinolytic Agents (administration & dosage)</term><term>Fibrinolytic Agents (therapeutic use)</term><term>Heparin (administration & dosage)</term><term>Heparin (analogs & derivatives)</term><term>Heparin (therapeutic use)</term><term>Indium Radioisotopes (analysis)</term><term>Male</term><term>Microscopy, Electron, Scanning</term><term>Models, Animal</term><term>Platelet Adhesiveness (drug effects)</term><term>Proteoglycans (administration & dosage)</term><term>Proteoglycans (therapeutic use)</term><term>Rats</term><term>Rats, Inbred BN</term><term>Rats, Inbred Strains</term><term>Thrombosis (prevention & control)</term><term>Vascular Patency (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Fibrinolytic Agents</term><term>Heparin</term><term>Proteoglycans</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Heparin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Indium Radioisotopes</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Platelet Adhesiveness</term><term>Vascular Patency</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Thrombosis</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Femoral Artery</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Fibrinolytic Agents</term><term>Heparin</term><term>Proteoglycans</term></keywords><keywords scheme="MESH" qualifier="ultrastructure" xml:lang="en"><term>Femoral Artery</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Topical</term><term>Anastomosis, Surgical</term><term>Animals</term><term>Blood Coagulation Tests</term><term>Male</term><term>Microscopy, Electron, Scanning</term><term>Models, Animal</term><term>Rats</term><term>Rats, Inbred BN</term><term>Rats, Inbred Strains</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Previously, during blood perfusion over collagen-coated surfaces; soluble or immobilized heparin proteoglycans (HEP-PG) have been shown to block thrombus growth. Our aim was to study the antithrombotic effect of locally applied unfractionated heparin (UFH, 1 mg/ml), or rat mast cell-derived HEP-PG (MW 750 kD, 10 microg/ml) compared with saline in early (10 min) and late (3 days) thrombus formation upon anastomosis of rat common femoral arteries. In both semiquantitative scanning electron microscopy (SEM) and quantitative platelet Indium 111-labeling HEP-PG inhibited thrombus growth in comparison with saline. At 10 min, the extent of thrombosis (scale 1-4) in SEM followed the order: saline (3.2+/-0.8) > UFH (2.8+/-1.0) > HEP-PG (1.8+/-0.8), and also Indium 111-positive platelets (10(6)) accumulated on the anastomosed vessel in the same order 14.2 +/-7.2, 10.3 +/-5.0, and 7.7 +/-3.1 (saline vs. HEP-PG, p = 0.03 and 0.05, respectively). At 3 days all HEP-PG-treated vessels remained patent with only small mural thrombi, whereas 2/7 saline- and 1/7 UFH-treated anastomoses occluded and showed more thrombosis overall. We conclude that locally administered HEP-PG inhibit arterial thrombus growth in anastomosed small-sized arteries and could prevent thrombotic complications in (micro)vascular surgery and arteriovenous shunts.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">11858484</PMID><DateCreated><Year>2002</Year><Month>02</Month><Day>22</Day></DateCreated><DateCompleted><Year>2002</Year><Month>09</Month><Day>06</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0340-6245</ISSN><JournalIssue CitedMedium="Print"><Volume>87</Volume><Issue>2</Issue><PubDate><Year>2002</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Thrombosis and haemostasis</Title><ISOAbbreviation>Thromb. Haemost.</ISOAbbreviation></Journal><ArticleTitle>Topically administered macromolecular heparin proteoglycans inhibit thrombus growth in microvascular anastomoses.</ArticleTitle><Pagination><MedlinePgn>245-51</MedlinePgn></Pagination><Abstract><AbstractText>Previously, during blood perfusion over collagen-coated surfaces; soluble or immobilized heparin proteoglycans (HEP-PG) have been shown to block thrombus growth. Our aim was to study the antithrombotic effect of locally applied unfractionated heparin (UFH, 1 mg/ml), or rat mast cell-derived HEP-PG (MW 750 kD, 10 microg/ml) compared with saline in early (10 min) and late (3 days) thrombus formation upon anastomosis of rat common femoral arteries. In both semiquantitative scanning electron microscopy (SEM) and quantitative platelet Indium 111-labeling HEP-PG inhibited thrombus growth in comparison with saline. At 10 min, the extent of thrombosis (scale 1-4) in SEM followed the order: saline (3.2+/-0.8) > UFH (2.8+/-1.0) > HEP-PG (1.8+/-0.8), and also Indium 111-positive platelets (10(6)) accumulated on the anastomosed vessel in the same order 14.2 +/-7.2, 10.3 +/-5.0, and 7.7 +/-3.1 (saline vs. HEP-PG, p = 0.03 and 0.05, respectively). At 3 days all HEP-PG-treated vessels remained patent with only small mural thrombi, whereas 2/7 saline- and 1/7 UFH-treated anastomoses occluded and showed more thrombosis overall. We conclude that locally administered HEP-PG inhibit arterial thrombus growth in anastomosed small-sized arteries and could prevent thrombotic complications in (micro)vascular surgery and arteriovenous shunts.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Olsson</LastName><ForeName>Eija</ForeName><Initials>E</Initials><Affiliation>Department of Plastic Surgery, Helsinki University Central Hospital, Finland.</Affiliation></Author><Author ValidYN="Y"><LastName>Asko-Seljavaara</LastName><ForeName>Sirpa</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lassila</LastName><ForeName>Riitta</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Comparative Study</PublicationType><PublicationType>Journal Article</PublicationType><PublicationType>Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Thromb Haemost</MedlineTA><NlmUniqueID>7608063</NlmUniqueID><ISSNLinking>0340-6245</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Fibrinolytic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Proteoglycans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>heparin proteoglycan</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance>Heparin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Administration, Topical</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Anastomosis, Surgical</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Blood Coagulation Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Femoral Artery</DescriptorName><QualifierName MajorTopicYN="N">surgery</QualifierName><QualifierName MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Fibrinolytic Agents</DescriptorName><QualifierName MajorTopicYN="N">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Heparin</DescriptorName><QualifierName MajorTopicYN="N">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Microscopy, Electron, Scanning</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Platelet Adhesiveness</DescriptorName><QualifierName MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Proteoglycans</DescriptorName><QualifierName MajorTopicYN="N">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Rats, Inbred BN</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Rats, Inbred Strains</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Thrombosis</DescriptorName><QualifierName MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Vascular Patency</DescriptorName><QualifierName MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>2</Month><Day>23</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>9</Month><Day>7</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>2</Month><Day>23</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11858484</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003432 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003432 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:11858484
|texte= Topically administered macromolecular heparin proteoglycans inhibit thrombus growth in microvascular anastomoses.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:11858484" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |